TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22382341

Group type: EXPERIMENTAL
Intervention: CE-224,535 (500 mg bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19727904

Group type: EXPERIMENTAL
Intervention: 67.5 mmol of bicarbonate daily for 3 months
Number of subjects: 162

Group type: COMPARATOR
Intervention: No bicarbonate
Number of subjects: 162
Study: 17953887

Group type: EXPERIMENTAL
Intervention: Implantation of circulatory assist devices as a permanent alternative to heart transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New generations of rotator pumps
Number of subjects: 0
Study: 16848262

Group type: EXPERIMENTAL
Intervention: 20 microl acidified thiourea and 20 microl 30 per cent w/w hydrogen peroxide (Group 5)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 20 microl acidified thiourea and 20 microl one per cent sodium hypochlorite (Group 6)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 20 microl acidified thiourea, 20 microl one per cent sodium hypochlorite and 20 microl 30 per cent w/w hydrogen peroxide (Group 7)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 20 microl 30 per cent w/w hydrogen peroxide (Group 2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 20 microl 30 per cent w/w hydrogen peroxide and thermocatalytically activated (Group 3)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Negative control (Group 1)
Number of subjects: 35
Study: 14620212

Group type: EXPERIMENTAL
Intervention: Canine-guided dentures
Number of subjects: 22

Group type: COMPARATOR
Intervention: Balanced occlusion dentures
Number of subjects: 22
Study: 10752972

Group type: EXPERIMENTAL
Intervention: Delavirdine treatment
Number of subjects: 1112
Study: 8883526

Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/ml (IOD-270)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mg I/ml (IOD-320)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iohexol 300 mg I/ml (IOH-300)
Number of subjects: 0
Study: 1610009

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram.kg‐1) in group 1 (normal function)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram.kg‐1) in group 2 (abnormal function)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo in group 1 (normal function)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo in group 2 (abnormal function)
Number of subjects: 115
Study: 3984919

Group type: EXPERIMENTAL
Intervention: 90 mg of ascorbic acid for 1 day followed by 250 mg/day for 2 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 90 mg of ascorbic acid for 1 day followed by 500 mg/day for 2 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 90 mg of ascorbic acid for 1 day followed by 1000 mg/day for 2 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: unsupplemented for 1 day followed by 0 mg ascorbic acid supplement for 2 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: unsupplemented for 1 day followed by 90 mg ascorbic acid supplement for 2 days
Number of subjects: 25
Study: 30894226

Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygen saturation (crSO2) monitoring combined with defined treatment guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard monitoring and treatment as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygen saturation (crSO2) monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Defined treatment guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mortality or cerebral injury (or both) defined as any intra-ventricular bleeding or cystic periventricular leukomalacia (or both)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neonatal morbidities
Number of subjects: 0
Study: 27548784

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM) affixed to the anterior surface of the lower limbs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM) affixed to the posterior surface of the lower limbs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No resistance (unloaded sprints)
Number of subjects: 19
Study: 25539986

Group type: EXPERIMENTAL
Intervention: Microinjections of HA salts of biotechnological origin, once weekly for 4 weeks and then once monthly for 4 months (group A) or 9 months (group B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Microinjections of HA salts of biotechnological origin, after an additional 4 months of monthly injections
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Microinjections of HA salts of biotechnological origin, in patients from group B that completed 10 months of treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline solution injected into the dorsum of the other hand (control)
Number of subjects: 22
Study: 23451990

Group type: EXPERIMENTAL
Intervention: nHA of particle size 10 to 100 nm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nHA with 24% EDTA treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Composite graft of nHA and β‐TCP (particle size 63 to 150 nm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Composite graft of nHA and β‐TCP with 24% EDTA treatment
Number of subjects: 60
Study: 21330457

Group type: EXPERIMENTAL
Intervention: SNP rs11046966 from the SOX5 gene
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Sox5(‐/‐) mice
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control group (424 control smokers)
Number of subjects: 810
Study: 19057413

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20.0 mg/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 17293605

Group type: EXPERIMENTAL
Intervention: Teaching intervention (small group discussion)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Teaching intervention (structured feedback on student-patient interview)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Teaching intervention (general teaching methods)
Number of subjects: 15
Study: 15488052

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 18
Study: 11238495

Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg) plus alendronate (10 mg)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: MK-677 plus alendronate
Number of subjects: 292
Study: 9587118

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration cytology (FNAC) and 14-gauge core needle biopsy (CB)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Open surgical biopsy (OSB)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis rate
Number of subjects: 823
Study: 7822672

Group type: EXPERIMENTAL
Intervention: Thin disposable soft contact lenses (0.07 mm thickness)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard disposable soft contact lenses (0.105 mm thickness)
Number of subjects: 10
Study: 2977527

Group type: EXPERIMENTAL
Intervention: Zoladex (3.6 mg depot administered every four weeks for 3 times)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (300 mg diethylstilbestrol diphosphate orally daily for 12 weeks or orchidectomy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 30688407

Group type: EXPERIMENTAL
Intervention: Corneal epithelial stem cells cultured on amniotic membrane (AM) with systemic immunosuppression
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group: Amniotic membrane (AM) only with systemic immunosuppression
Number of subjects: 16
Study: 29553442

Group type: EXPERIMENTAL
Intervention: Text-message reminder intervention
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No text-message reminder (baseline)
Number of subjects: 1000
Study: 26976446

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (untreated cells)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (clinical study)
Number of subjects: 12
Study: 25098569

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention including SMS coaching, USSD questionnaire, and family planning information via SMS and Mxit.
Number of subjects: 234
Study: 22922775

Group type: EXPERIMENTAL
Intervention: Prednisone (PRED) 40 mg/m²/day for 28 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 6 mg/m²/day for 28 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (16 children without ALL)
Number of subjects: 29
Study: 20061337

Group type: EXPERIMENTAL
Intervention: Closed circuits without cardiotomy suction (closed group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open circuits with open reservoirs and cardiotomy suction (open group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open circuits (open group)
Number of subjects: 30
Study: 18685360

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newer regimens (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Addition of a third agent to doublet combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: New drugs (pemetrexed and vinflunine)
Number of subjects: 0
Study: 16381354

Group type: EXPERIMENTAL
Intervention: Stapled laparoscopic hernia repair
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unstapled laparoscopic hernia repair
Number of subjects: 49
Study: 11908539

Group type: EXPERIMENTAL
Intervention: High participation units (n = 18)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low participation units (n = 10)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control units (no formalized research groups or activities)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: All units (high, low, and control)
Number of subjects: 235
Study: 10442371

Group type: EXPERIMENTAL
Intervention: UFT (300 mg/day) plus oral calcium folinate (90 mg/day) and vinorelbine (15 mg/m2)
Number of subjects: 0
Study: 7531223

Group type: EXPERIMENTAL
Intervention: PVP16B (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5 + bleomycin 30 IU/wk for 9 consecutive weeks)
Number of subjects: 178

Group type: COMPARATOR
Intervention: PVP16 (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PVP16B
Number of subjects: 178

Group type: COMPARATOR
Intervention: PVP16
Number of subjects: 178
Study: 2193271

Group type: EXPERIMENTAL
Intervention: estrone sulfate 0.625 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: estrone sulfate 1.25 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 153
Study: 387204

Group type: EXPERIMENTAL
Intervention: 5 FU infusion with mitomycin-C
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 FU infusion with methyl-CCNU
Number of subjects: 0
Study: 31389859

Group type: EXPERIMENTAL
Intervention: Group A1 (80 kVp, 40 mL CM, iterative reconstruction)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group A2 (80 kVp, 40 mL CM, AI-based noise reduction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group B (120 kVp, 80 mL CM, iterative reconstruction)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group A (combined A1 and A2)
Number of subjects: 60
Study: 29995458

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g/day) for 6 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 26914909

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 3924

Group type: EXPERIMENTAL
Intervention: Emtricitabine-Tenofovir Disoproxil Fumarate (FTC-TDF)
Number of subjects: 3924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3924
Study: 25185586

Group type: EXPERIMENTAL
Intervention: Individualised physical activity on prescription
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study: 22378483

Group type: EXPERIMENTAL
Intervention: Baseline demographic and clinical variables
Number of subjects: 539
Study: 20705231

Group type: EXPERIMENTAL
Intervention: EASE intervention (n=153)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control intervention (n=139)
Number of subjects: 292
Study: 17541110

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 0
Study: 16388724

Group type: EXPERIMENTAL
Intervention: Oral terbinafine (250 mg/day) for 6 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 174
Study: 17293471

Group type: EXPERIMENTAL
Intervention: BTB autograft
Number of subjects: 71

Group type: COMPARATOR
Intervention: ST autograft
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both BTB and ST autografts
Number of subjects: 71
Study: 11081335

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 9
Study: 8783533

Group type: EXPERIMENTAL
Intervention: FluroShield
Number of subjects: 86

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 86
Study: 1537129

Group type: EXPERIMENTAL
Intervention: Alteplase plus heparin
Number of subjects: 334

Group type: COMPARATOR
Intervention: Alteplase plus placebo
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Heparin with adequate anticoagulation
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Heparin with patent vessels
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Heparin with recurrent ischemia
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Heparin with left ventricular thrombosis
Number of subjects: 334
Study: 6733194

Group type: EXPERIMENTAL
Intervention: Imagined lifting a 16 gram or 35 gram weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actual lifting of a 16 gram or 35 gram weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adopting an agreeable attitudinal set while reading neutral text
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adopting a disagreeable attitudinal set while reading neutral text
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagining reading an editorial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silently reading neutral text
Number of subjects: 0
Study: 30980133

Group type: EXPERIMENTAL
Intervention: Instructed run sprint interval training (INT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both INT and MICT
Number of subjects: 29
Study: 28752580

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 55

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 55
Study: 27460620

Group type: EXPERIMENTAL
Intervention: Group Coping-Oriented Therapy (COP)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Supportive Therapy (SUP)
Number of subjects: 196
Study: 24636483

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23342561

Group type: EXPERIMENTAL
Intervention: Precaine (8% Lidocaine + 0.8% Dibucaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Precaine B (20% Benzocaine)
Number of subjects: 60
Study: 20393432

Group type: EXPERIMENTAL
Intervention: Rotigotine, a dopaminergic drug, dosage and duration not specified
Number of subjects: 0
Study: 18690809

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nephrostomy drainage
Number of subjects: 65
Study: 15714982

Group type: EXPERIMENTAL
Intervention: Docetaxel as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel combined with estramustine or other antimicrotubular agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with prednisone
Number of subjects: 0
Study: 12846341

Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 25
Study: 10377207

Group type: EXPERIMENTAL
Intervention: fluticasone metered dose inhaler (pMDI) 250 microg, 8 puffs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: fluticasone pMDI 250 microg, 8 puffs + mouth rinsing/gargling (water)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: fluticasone pMDI 250 microg, 8 puffs + mouth rinsing/gargling (charcoal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo pMDI, 8 puffs + mouth rinsing/gargling (water)
Number of subjects: 16
Study: 8710072

Group type: EXPERIMENTAL
Intervention: Tacrine > 80 mg/d
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Tacrine > 120 mg/d
Number of subjects: 663
Study: 2029947

Group type: EXPERIMENTAL
Intervention: School-based clinics providing reproductive health services
Number of subjects: 0

Group type: COMPARATOR
Intervention: School-based clinics providing contraceptives on site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic school with strong AIDS education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic school prioritizing pregnancy prevention with contraceptive vouchers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic school focusing on high-risk youth and dispensing birth control pills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall impact of clinics on pregnancy rates
Number of subjects: 0
Study: 30945822

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 28542285

Group type: EXPERIMENTAL
Intervention: iLook Out for Child Abuse educational intervention
Number of subjects: 762

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 762
Study: 26121561

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 4158

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 4158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4158
Study: 23874572

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21285532

Group type: EXPERIMENTAL
Intervention: Newly-licensed vaccine (Fluarix™)
Number of subjects: 1845

Group type: COMPARATOR
Intervention: Established vaccine
Number of subjects: 1845
Study: 19583486

Group type: EXPERIMENTAL
Intervention: Fluoxetine in patients with normal thyroid function (n=15)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sertraline in patients with normal thyroid function (n=14)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fluoxetine in patients with hypothyroidism (n=13)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sertraline in patients with hypothyroidism (n=15)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n=10) with hypothyroidism on levothyroxine therapy without depression
Number of subjects: 67
Study: 17377119

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: saline
Number of subjects: 56
Study: 15264733

Group type: EXPERIMENTAL
Intervention: Dexamethasone 50 microg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dexamethasone 100 microg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dexamethasone 200 microg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dexamethasone 250 microg/kg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dexamethasone (all dosages)
Number of subjects: 210
Study: 11554953

Group type: EXPERIMENTAL
Intervention: 20 U botulinum toxin injected into frontal and temporal muscles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9754972

Group type: EXPERIMENTAL
Intervention: High-Impact (HIP) aerobic dance session
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-Impact (LIP) aerobic dance session
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison between HIP and LIP sessions
Number of subjects: 10
Study: 8140666

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 123
Study: 3169222

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ambient air (placebo with noisy nebulizer)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-treatment (air without nebulizer)
Number of subjects: 24
Study: 31162898

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral supine mini-percutaneous nephrolithotomy (n=37)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Staged mini-percutaneous nephrolithotomy (n=42)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Main group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 28657803

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) - 50 min cycling at 75% VO2peak
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Strength exercise (SE) - 10 × 8 leg extensions at 75% 1RM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined exercise (CE) - 50% SE + 50% AE
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonexercise control (CON) - 50 min seated rest
Number of subjects: 12
Study: 25709702

Group type: EXPERIMENTAL
Intervention: Ice massage applied to LI4 during four contractions
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Placebo group with pressure applied to LI4 using silicone balloons
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 150
Study: 23453404

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg single dose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Everolimus (adjusted doses based on Child‐Pugh classification)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Thresholds for dose adjustment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adverse events assessment
Number of subjects: 34